Lack of vitamin D predicts impaired long-term immune response to COVID-19 vaccination.


Journal

Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444

Informations de publication

Date de publication:
12 2023
Historique:
received: 14 06 2023
accepted: 04 08 2023
medline: 2 11 2023
pubmed: 18 8 2023
entrez: 17 8 2023
Statut: ppublish

Résumé

Low vitamin D levels were reported to negatively influence the outcome of acute COVID-19, as well as to be linked to Long-COVID. However, few studies have investigated, so far, its effects on humoral-response to anti-SARS-CoV-2 vaccination, reporting conflicting results. We aimed to evaluate the impact of baseline 25(OH)vitamin D (25(OH)D) levels on humoral-response to a two-dose cycle of Pfizer-BioNTech-vaccine up to 9-10 months after immunization. We retrospectively included 119 consecutive healthcare-workers (median age 53 years) without a previous history of acute COVID-19 or anti-SARS-CoV-2 immunoglobulins presence immunized with two doses of Comirnaty-vaccine from January to February 2021. 25(OH)D was measured at time of first-immunization. Immune response was evaluated at: time 0 (T0), before the first-dose; T1, time of second-dose (21 days after T0); T2, T3, T4 at 1, 5 and 9 months after T1, respectively. Median 25(OH)D levels were 25.6 ng/mL, and vitamin D deficiency (25(OH)D <20 ng/mL) was observed in 29 subjects (24.8%). In those with vitamin D deficiency, we found a non-significant trend towards lower antibody-titers at T3, and significantly lower titers at T4 as compared to those not vitamin D-deficient, also observing a more pronounced antibody-titers negative drop from peak-T2 and T4 in those with vitamin D deficiency. A positive correlation between 25(OH)D levels and antibody-titers at T4 (p = 0.043) was found. In multiple linear-regression analysis, 25(OH)D deficiency and older-age resulted as negative independent factors associated with antibody titer at T4 (p = 0.026, p = 0.004; respectively). In our relatively young cohort presenting low prevalence of hypovitaminosis D, the long-term humoral response to anti-SARS-CoV-2 vaccination was negatively influenced by low baseline 25(OH)D. Vitamin D supplementation could be tested as a strategy to optimize the vaccination campaigns to prevent severe COVID-19.

Identifiants

pubmed: 37592162
doi: 10.1007/s12020-023-03481-w
pii: 10.1007/s12020-023-03481-w
pmc: PMC10618322
doi:

Substances chimiques

Vitamin D 1406-16-2
COVID-19 Vaccines 0
Vitamins 0

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

536-541

Commentaires et corrections

Type : CommentOn

Informations de copyright

© 2023. The Author(s).

Références

Biomedicines. 2022 Aug 17;10(8):
pubmed: 36009540
Front Public Health. 2022 Nov 15;10:1072137
pubmed: 36457318
Front Immunol. 2021 Apr 15;12:633184
pubmed: 33936045
Nat Rev Nephrol. 2022 Nov;18(11):708-723
pubmed: 35999285
Curr Transplant Rep. 2022;9(3):174-184
pubmed: 35506151
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Curr Res Transl Med. 2022 Jul;70(3):103344
pubmed: 35390564
Nat Rev Endocrinol. 2021 Aug;17(8):445-446
pubmed: 34079100
Nat Rev Clin Oncol. 2022 Jun;19(6):385-401
pubmed: 35277694
PLoS One. 2020 Dec 31;15(12):e0244126
pubmed: 33382764
Br J Clin Pharmacol. 2018 Oct;84(10):2194-2207
pubmed: 29851137
JBMR Plus. 2020 Nov 10;4(12):e10417
pubmed: 33354643
J Clin Endocrinol Metab. 2023 Apr 13;108(5):1034-1042
pubmed: 36477486
Front Immunol. 2022 Sep 13;13:965971
pubmed: 36177017
J Clin Endocrinol Metab. 2022 Jan 1;107(1):e348-e360
pubmed: 34383926
Endocrine. 2022 Nov;78(2):247-254
pubmed: 35857271
Eur J Endocrinol. 2020 Nov;183(5):R133-R147
pubmed: 32755992
Endocrine. 2021 May;72(2):301-316
pubmed: 33963516
J Immunol Methods. 2022 Jul;506:113293
pubmed: 35660546
Sci Rep. 2022 Apr 5;12(1):5699
pubmed: 35383273
Kidney Int. 2022 May;101(5):883-894
pubmed: 35176326
Endocr Rev. 2019 Aug 1;40(4):1109-1151
pubmed: 30321335
Rev Endocr Metab Disord. 2021 Dec;22(4):1201-1218
pubmed: 34940947
Nutrients. 2018 Mar 26;10(4):
pubmed: 29587438
Endocrine. 2021 Feb;71(2):267-269
pubmed: 33452994
J Clin Endocrinol Metab. 2023 Sep 18;108(10):e1106-e1116
pubmed: 37051747
Front Immunol. 2021 Dec 06;12:758294
pubmed: 34938287
Endocrine. 2023 Jan;79(1):31-44
pubmed: 36287374
Vaccines (Basel). 2021 Nov 19;9(11):
pubmed: 34835288
Int J Environ Res Public Health. 2022 Feb 07;19(3):
pubmed: 35162875
J Clin Lab Anal. 2022 May;36(5):e24363
pubmed: 35334493
Endocrine. 2023 Jun;80(3):669-683
pubmed: 36854858
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Vaccines (Basel). 2022 Sep 23;10(10):
pubmed: 36298466

Auteurs

Luigi di Filippo (L)

Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS Hospital, Milano, Italy.

Stefano Frara (S)

Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS Hospital, Milano, Italy.

Umberto Terenzi (U)

Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS Hospital, Milano, Italy.

Fabrizio Nannipieri (F)

Clinical Research, Abiogen Pharma, Pisa, Italy.

Massimo Locatelli (M)

Laboratory Medicine Service, IRCCS San Raffaele Hospital, Milano, Italy.

Fabio Ciceri (F)

Hematology and Bone Marrow Transplant Unit, San Raffaele Vita-Salute University and IRCCS Hospital, Milano, Italy.

Andrea Giustina (A)

Institute of Endocrine and Metabolic Sciences, San Raffaele Vita-Salute University and IRCCS Hospital, Milano, Italy. giustina.andrea@hsr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH